Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial

Journal of Psychiatric Research

Volumn 45, Issue 7, 2011, Pages 896-901

  Blumberger, Daniel M ^a   Mulsant, Benoit H ^a,b   Emeremni, Chetachi ^b   Houck, Patricia ^b   Andreescu, Carmen ^b   Mazumdar, Sati ^b   Whyte, Ellen ^b   Rothschild, Anthony J s ^c   Flint, Alastair J ^a,d   Meyers, Barnett S ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Pharmacotherapy; Psychotic depression; Treatment resistance

Indexed keywords

OLANZAPINE; PLACEBO; SERTRALINE;

ADULT; ARTICLE; DEPRESSIVE PSYCHOSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME;

EID: 79958752394     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.01.003     Document Type: Article

References (34)

1. Amsterdam J.D., Williams D., Michelson D., Adler L.A., Dunner D.L., Nierenberg A.A., et al. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology 2009, 59:227-233.
2. Andreescu C., Mulsant B.H., Peasley-Miklus C., Rothschild A.J., Flint A.J., Heo M., et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry 2007, 68:194-200.
3. Arean P.A., Raue P., Mackin R.S., Kanellopoulos D., McCulloch C., Alexopoulos G.S. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction. The American Journal of Psychiatry 2010, 167:1391-1398.
4. Coryell W., Leon A., Winokur G., Endicott J., Keller M., Akiskal H., Solomon D. Importance of psychotic features to long-term course in major depressive disorder. The American Journal of Psychiatry 1996, 153:483-489.
5. Davis J.M., Chen N. Dose response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 2004, 24:192-208.
6. Dombrovski A.Y., Mulsant B.H., Haskett R.F., Prudic J., Begley A.E., Sackeim H.A. Predictors of remission after electroconvulsive therapy in unipolar major depression. Journal of Clinical Psychiatry 2005, 66:1043-1049.
7. Endicott J., Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Archives of General Psychiatry 1978, 35:837-844.
8. First M.B., Spitzer RL., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
9. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state - practical method for grading cognitive state of patients for clinician. Journal of Psychiatric Research 1975, 12:189-198.
10. Guy W. ECDEU assessment manual for psychopharmacology, revised 1976, Department of Health, Education, and Welfare, Rockville, MD, (pp. Document no. ADM 76-338.).
11. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960, 23:56-62.
12. Hennings J.M., Owashi T., Binder E.B., Horstmann S., Menke A., Kloiber S., et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. Journal of Psychiatric Research 2009, 43:215-229.
13. Kellner C.H., Knapp R.G., Petrides G., Rummans T.A., Husain M.M., Rasmussen K., et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression - A multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Archives of General Psychiatry 2006, 63:1337-1344.
14. Keshavan M.S., Haas G., Miewald J., Montrose D.M., Reddy R., Schooler N.R., Sweeney J.A. Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. Schizophrenia Bulletin 2003, 29:757-769.
15. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA: The Journal of the American Medical Association 2003, 289:3095-3105.
16. Kupfer D.J. Achieving adequate outcomes in geriatric depression: standardized criteria for remission. Journal of Clinical Psychopharmacology 2005, 25:S24-S28.
17. Meyers B.S., English J., Gabriele M., Peasley-Miklus C., Heo M., Flint A.J., et al. A delusion assessment scale for psychotic major depression: reliability, validity, and utility. Biological Psychiatry 2006, 60:1336-1342.
18. Meyers B.S., Flint A.J., Rothschild A.J., Mulsant B.H., Whyte E.M., Peasley-Miklus C., et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry 2009, 66:838-847.
19. Miller M.D., Paradis C.F., Houck P.R., Mazumdar S., Stack J.A., Rifai A.H., et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Research 1992, 41:237-248.
20. Nelson J.C., Price L.H., Jatlow P.I. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. American Journal of Psychiatry 1986, 143:1151-1154.
21. Oquendo M.A., Baca-Garcia E., Kartachov A., Khait V., Campbell C.E., Richards M., et al. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Journal of Clinical Psychiatry 2003, 64:825-833.
22. Oquendo M.A., Malone K.M., Ellis S.P., Sackeim H.A., Mann J.J. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. American Journal of Psychiatry 1999, 156:190-194.
23. Patten S.B., Wang J.L., Williams J.V., Currie S., Beck C.A., Maxwell C.J., El-Guebaly N. Descriptive epidemiology of major depression in Canada. Canadian Journal of Psychiatry 2006, 51:84-90.
24. Petrides G., Fink M., Husain M.M., Knapp R.G., Rush A.J., Mueller M., et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. Journal of Extracorporeal Technology 2001, 17:244-253.
25. Prudic J., Haskett R.F., Mulsant B., Malone K.M., Pettinati H.M., Stephens S., et al. Resistance to antidepressant medications and short-term clinical response to ECT. American Journal of Psychiatry 1996, 153:985-992.
26. Rasmussen K.G., Mueller M., Knapp R.G., Husain M.M., Rummans T.A., Sampson S.M., et al. Antidepressant medication treatment failure does not predict lower remission with ECT for major depressive disorder: a report from the consortium for research in electroconvulsive therapy. Journal of Clinical Psychiatry 2007, 68:1701-1706.
27. Reynolds C.F., Frank E., Kupfer D.J., Thase M.E., Perel J.M., Mazumdar S., Houck P.R. Treatment outcome in recurrent major depression: a post hoc comparison of elderly (" young old" ) and midlife patients. American Journal of Psychiatry 1996, 153:1288-1292.
28. Roose S.P., Sackeim H.A., Krishnan K.R.R., Pollock B.G., Alexopoulos G., Lavretsky H., et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. American Journal of Psychiatry 2004, 161:2050-2059. Old-Old Depression Study, G.
29. Rothschild A.J. Challenges in the treatment of depression with psychotic features. Biological Psychiatry 2003, 53:680-690.
30. Sackeim H.A., Haskett R.F., Mulsant B.H., Thase M.E., Mann J.J., Pettinati H.M., et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA: The Journal of the American Medical Association 2001, 285:1299-1307.
31. Schimmelmann B.G., Huber C.G., Lambert M., Cotton S., McGorry P.D., Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. Journal of Psychiatric Research 2008, 42:982-990.
32. Spiker D.G., Weiss J.C., Dealy R.S., Griffin S.J., Hanin I., Neil J.F., et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry 1985, 142:430-436.
33. Tew J.D., Mulsant B.H., Houck P.R., Lenze E., Whyte E.M., Miller M.D., et al. Impact of prior treatment exposure on response to antidepressant treatment in late life. American Journal of Geriatric Psychiatry 2006, 14:957-965.
34. Williams J.B., Kobak K.A., Bech P., Engelhardt N., Evans K., Lipsitz J., et al. The GRID-HAMD: standardization of the Hamilton depression rating scale. International Clinical Psychopharmacology 2008, 23:120-129.